Pulmonary Embolism Therapeutics Market Size, Share, Trends, Growth Outlook

Pulmonary Embolism Therapeutics Market is estimated to increase at a growth rate of 8.8% CAGR over the forecast period from 2024 to 2030.

The global Pulmonary Embolism Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Application (Hospitals, Ambulatory surgical centers, Research institutes), By Route of Administration (Oral, Parenteral).

An Introduction to Pulmonary Embolism Therapeutics Market in 2024

Pulmonary embolism (PE) is a life-threatening condition caused by the obstruction of pulmonary arteries by blood clots. The Pulmonary Embolism Therapeutics Market comprises a range of pharmacological interventions, including anticoagulants, thrombolytics, and supportive therapies, aimed at preventing, treating, and managing PE-related complications. The market is driven by the increasing incidence of venous thromboembolism, advancements in diagnostic techniques, and the introduction of novel therapeutic agents with improved safety and efficacy profiles. Key players in the market are focusing on research and development efforts to optimize treatment protocols, enhance patient outcomes, and reduce the risk of recurrent pulmonary embolism.

Pulmonary Embolism Therapeutics Market Competitive Landscape

The global Pulmonary Embolism Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Pulmonary Embolism Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Pulmonary Embolism Therapeutics Industry include- Amgen Inc, Anthos Therapeutics, argenx SE, Astellas Pharma Inc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd, Eli Lilly and Co., F. Hoffmann La Roche Ltd, Gilead Sciences Inc, Inari Medical Inc, Johnson and Johnson Services Inc, Medtronic Plc.

Pulmonary Embolism Therapeutics Market Trend: Adoption of Anticoagulant Therapy

In the realm of pulmonary embolism (PE) therapeutics, a significant trend is the widespread adoption of anticoagulant therapy as the standard treatment approach. Pulmonary embolism is a life-threatening condition characterized by the obstruction of pulmonary arteries by blood clots, leading to impaired blood flow to the lungs. Anticoagulant medications, such as heparin and direct oral anticoagulants (DOACs), are commonly used to prevent further clot formation and reduce the risk of recurrent thromboembolic events in patients with PE. Recent advancements in anticoagulant therapy include the development of DOACs, which offer advantages such as oral administration, predictable pharmacokinetics, and fewer drug interactions compared to traditional anticoagulants. This trend towards the adoption of anticoagulant therapy reflects the growing recognition of its efficacy and safety in the management of PE.

Pulmonary Embolism Therapeutics Market Driver: Increasing Incidence of Venous Thromboembolism

The increasing incidence of venous thromboembolism (VTE), including pulmonary embolism, serves as a significant market driver for PE therapeutics. Venous thromboembolism is a common cardiovascular disorder with significant morbidity and mortality, affecting millions of individuals worldwide each year. Risk factors such as surgery, trauma, immobilization, cancer, and inherited thrombophilias contribute to the development of VTE and PE. As the population ages and the prevalence of risk factors such as obesity and sedentary lifestyles increases, the incidence of VTE and PE is expected to rise accordingly. Consequently, there's a growing demand for effective therapeutic interventions that can prevent and treat PE, reduce morbidity and mortality, and improve long-term outcomes for patients with this life-threatening condition. This driver underscores the critical need for advancements in PE therapeutics to address the evolving clinical needs of patients and healthcare providers.

Pulmonary Embolism Therapeutics Market Opportunity: Development of Novel Thrombolytic Agents

A promising opportunity in the pulmonary embolism therapeutics market lies in the development of novel thrombolytic agents that can rapidly dissolve blood clots and restore pulmonary blood flow in patients with acute PE. Thrombolytic therapy is reserved for patients with hemodynamically unstable PE or massive PE with evidence of right heart strain, where prompt clot dissolution is essential to prevent hemodynamic collapse and death. Current thrombolytic agents, such as alteplase and tenecteplase, have limitations such as bleeding risk, fibrin specificity, and dosing complexity. Investing in the discovery and development of novel thrombolytic agents with improved safety and efficacy profiles presents a strategic opportunity for pharmaceutical companies to address unmet medical needs in the management of acute PE and improve outcomes for patients at high risk of adverse events.

Pulmonary Embolism Therapeutics Market Share Analysis: Hospitals is the fastest growing market segment over the forecast period to 2030

In the realm of Pulmonary Embolism Therapeutics, the Hospitals segment emerges as the one experiencing the most rapid growth. Hospitals serve as the primary centers for the diagnosis, treatment, and management of pulmonary embolism due to their advanced medical infrastructure, specialized personnel, and access to emergency care facilities. With pulmonary embolism being a life-threatening condition requiring immediate intervention, hospitals play a crucial role in providing timely medical attention, including the administration of anticoagulant therapy, thrombolytic agents, and supportive care measures. Moreover, advancements in medical technology and the adoption of evidence-based treatment protocols within hospital settings have contributed to improved outcomes and enhanced patient survival rates. As a result, the hospitals segment is witnessing substantial growth in the demand for pulmonary embolism therapeutics, reinforcing its pivotal position in the healthcare landscape for addressing this critical condition effectively.

Pulmonary Embolism Therapeutics Market Segmentation

By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Pulmonary Embolism Therapeutics Companies

Amgen Inc
Anthos Therapeutics
argenx SE
Astellas Pharma Inc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Daiichi Sankyo Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
Inari Medical Inc
Johnson and Johnson Services Inc
Medtronic Plc
* List not Exhaustive

Reasons to Buy the Pulmonary Embolism Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Pulmonary Embolism Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Pulmonary Embolism Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Pulmonary Embolism Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Pulmonary Embolism Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Pulmonary Embolism Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Pulmonary Embolism Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Pulmonary Embolism Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Pulmonary Embolism Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Pulmonary Embolism Therapeutics Industry
4.2 Key Market Trends in Pulmonary Embolism Therapeutics Industry
4.3 Potential Opportunities in Pulmonary Embolism Therapeutics Industry
4.4 Key Challenges in Pulmonary Embolism Therapeutics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Pulmonary Embolism Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Pulmonary Embolism Therapeutics Market Outlook by Segments
7.1 Pulmonary Embolism Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
8 North America Pulmonary Embolism Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Pulmonary Embolism Therapeutics Markets in 2024
8.2 North America Pulmonary Embolism Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Pulmonary Embolism Therapeutics Market size Outlook by Segments, 2021-2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
9 Europe Pulmonary Embolism Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Pulmonary Embolism Therapeutics Markets in 2024
9.2 Europe Pulmonary Embolism Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Pulmonary Embolism Therapeutics Market Size Outlook by Segments, 2021-2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
10 Asia Pacific Pulmonary Embolism Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Pulmonary Embolism Therapeutics Markets in 2024
10.2 Asia Pacific Pulmonary Embolism Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Pulmonary Embolism Therapeutics Market size Outlook by Segments, 2021-2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
11 South America Pulmonary Embolism Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Pulmonary Embolism Therapeutics Markets in 2024
11.2 South America Pulmonary Embolism Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Pulmonary Embolism Therapeutics Market size Outlook by Segments, 2021-2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
12 Middle East and Africa Pulmonary Embolism Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Pulmonary Embolism Therapeutics Markets in 2024
12.2 Middle East and Africa Pulmonary Embolism Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Pulmonary Embolism Therapeutics Market size Outlook by Segments, 2021-2030
By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen Inc
Anthos Therapeutics
argenx SE
Astellas Pharma Inc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Daiichi Sankyo Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
Inari Medical Inc
Johnson and Johnson Services Inc
Medtronic Plc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Application
Hospitals
Ambulatory surgical centers
Research institutes
By Route of Administration
Oral
Parenteral